Neoplasm Metastasis
310
15
27
185
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
54 trials with published results (17%)
Research Maturity
185 completed trials (60% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.6%
39 terminated out of 310 trials
82.6%
-3.9% vs benchmark
14%
44 trials in Phase 3/4
29%
54 of 185 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 185 completed trials
Clinical Trials (310)
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Cognitive Outcome After SRS or WBRT in Patients With Multiple Brain Metastases (CAR-Study B)
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A Study of LY4175408 in Participants With Advanced Cancer
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
CIRSE Emprint Microwave Ablation Registry
CIRSE Registry for LifePearl Microspheres
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer
Do Patients Want to Engage in Discussions Dedicated to Anticipating (DDA) Their Preferences of Care in the Event of Worsening Health Status?